> Details

Wild, Mirjam G.; Kreidel, Felix; Hell, Michaela M.; Praz, Fabien; Mach, Markus; Adam, Matti; Reineke, David; Ruge, Hendrik; Ludwig, Sebastian; Conradi, Lenard; Rudolph, Tanja K.; Bleiziffer, Sabine; Kellermair, Jörg; Zierer, Andreas; Nickenig, Georg; Weber, Marcel; Petronio, Anna Sonia; Giannini, Cristina; Dahle, Gry; Rein, Kjell A.; Coisne, Augustin; Vincentelli, André; Dubois, Christophe; Duncan, Alison; [...]

Transapical mitral valve implantation for treatment of symptomatic mitral valve disease: a real‐world multicentre experience

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Transapical mitral valve implantation for treatment of symptomatic mitral valve disease: a real‐world multicentre experience
  • Contributor: Wild, Mirjam G.; Kreidel, Felix; Hell, Michaela M.; Praz, Fabien; Mach, Markus; Adam, Matti; Reineke, David; Ruge, Hendrik; Ludwig, Sebastian; Conradi, Lenard; Rudolph, Tanja K.; Bleiziffer, Sabine; Kellermair, Jörg; Zierer, Andreas; Nickenig, Georg; Weber, Marcel; Petronio, Anna Sonia; Giannini, Cristina; Dahle, Gry; Rein, Kjell A.; Coisne, Augustin; Vincentelli, André; Dubois, Christophe; Duncan, Alison; [...]
  • imprint: Wiley, 2022
  • Published in: European Journal of Heart Failure
  • Language: English
  • DOI: 10.1002/ejhf.2434
  • ISSN: 1388-9842; 1879-0844
  • Origination:
  • Footnote:
  • Description: <jats:sec><jats:title>Aims</jats:title><jats:p>Transcatheter mitral valve implantation (TMVI) is a new treatment option for patients with symptomatic mitral valve (MV) disease. Real‐world data have not yet been reported. This study aimed to assess procedural and 30‐day outcomes of TMVI in a real‐world patient cohort.</jats:p></jats:sec><jats:sec><jats:title>Method and results</jats:title><jats:p>All consecutive patients undergoing implantation of a transapically delivered self‐expanding valve at 26 European centres from January 2020 to April 2021 were included in this retrospective observational registry. Among 108 surgical high‐risk patients included (43% female, mean age 75 ± 7 years, mean STS‐PROM 7.2 ± 5.3%), 25% was treated for an off‐label indication (e.g. previous MV intervention or surgery, mitral stenosis, mitral annular calcification). Patients were highly symptomatic (New York Heart Association [NYHA] functional class III/IV in 86%) and mitral regurgitation (MR) was graded 3+/4+ in 95% (38% primary, 37% secondary, and 25% mixed aetiology). Technical success rate was 96%, and MR reduction to ≤1+ was achieved in all patients with successful implantation. There were two procedural deaths and 30‐day all‐cause mortality was 12%. At early clinical follow‐up, MR reduction was sustained and there were significant reductions of pulmonary pressure (systolic pulmonary artery pressure 52 vs. 42 mmHg, <jats:italic>p</jats:italic> &lt; 0.001), and tricuspid regurgitation severity (<jats:italic>p</jats:italic> = 0.013). Heart failure symptoms improved significantly (73% in NYHA class I/II, <jats:italic>p</jats:italic> &lt; 0.001). Procedural success rate according to MVARC criteria was 80% and was not different in patients treated for an off‐label indication (74% vs. 81% for off‐ vs. on‐label, <jats:italic>p</jats:italic> = 0.41).</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>In a real‐world patient population, TMVI has a high technical and procedural success rate with efficient and durable MR reduction and symptomatic improvement.</jats:p></jats:sec>
  • Access State: Open Access